Full-size Left-side Hidden
Conclusion

OPGs in children with NF1 represent both diagnostic and management challenges for clinicians. Whereas considerable progress has been made over the past decade in both our clinical and basic science understanding of these tumors, several key areas deserve future investigation. First, we need to be able to identify efficiently children at greatest risk for developing a symptomatic OPG. Second, these at-risk children require age-appropriate visual assessment tools to determine when they should be treated. Third, symptomatic children should be treated with agents that have maximal therapeutic efficacy against the tumor with minimal effects on the developing brain. Lastly, improved therapeutic strategies need to be developed for those children who fail initial treatment. With the advent of preclinical and clinical consortia focused on NF1, we are uniquely positioned to improve the future management of these children.